Local Antibiotic Delivery for Community Acquired Pneumonia (LANDCAP 2)

Conditions

Community-acquired pneumonia

Brief summary

Days alive and out of hospital at 14 days.

Detailed description

Days alive and out of hospital at 30 days., Days alive and out of hospital and without antibiotics at 30 days., Proportion of patient with antibiotic-related side-effects, Differences in gut microbiome diversity and composition in stool and oral samples on day 5 and on day 60., All-cause mortality at 30 days., Proportion of patients converted to guideline-based therapy according to algorithm as described in the section titled “Procedures, patient monitoring and data collection”., Proportion of patients readmitted, admitted to ICU or dead at 30 days., CRP on day 5, continuous and binary (higher than on any day from 1 to 4 including baseline)., MAP ≤ 65 OR respiratory frequency > 25 OR pulse > 100 OR needing supplemental oxygen (1-4 of these fulfilled) on day 5., PCT on day 5, continuous and binary (higher than on any day from 1 to 4 including baseline), Temperature ≥ 38.0 on day 5., Patient reported outcome measurements: Changes in Visual Analogue Scales for dyspnoea, cough, and fatigue from day 1 to day 5.

Related papers

No related papers found yet.

Interventions

DRUGSALINE

DRUGSODIUM CHLORIDE

DRUGQuinsair 240 mg nebuliser solution

DRUGPiperacillin/Tazobactam "Stada"

DRUGpulver til infusionsvæske

DRUGopløsning

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Days alive and out of hospital at 14 days.	—

Secondary

Measure	Time frame
Days alive and out of hospital at 30 days., Days alive and out of hospital and without antibiotics at 30 days., Proportion of patient with antibiotic-related side-effects, Differences in gut microbiome diversity and composition in stool and oral samples on day 5 and on day 60., All-cause mortality at 30 days., Proportion of patients converted to guideline-based therapy according to algorithm as described in the section titled “Procedures, patient monitoring and data collection”., Proportion of patients readmitted, admitted to ICU or dead at 30 days., CRP on day 5, continuous and binary (higher than on any day from 1 to 4 including baseline)., MAP ≤ 65 OR respiratory frequency > 25 OR pulse > 100 OR needing supplemental oxygen (1-4 of these fulfilled) on day 5., PCT on day 5, continuous and binary (higher than on any day from 1 to 4 including baseline), Temperature ≥ 38.0 on day 5., Patient reported outcome measurements: Changes in Visual Analogue Scales for dyspnoea, cough, and fatigue	—

Measure

Time frame

Days alive and out of hospital at 30 days., Days alive and out of hospital and without antibiotics at 30 days., Proportion of patient with antibiotic-related side-effects, Differences in gut microbiome diversity and composition in stool and oral samples on day 5 and on day 60., All-cause mortality at 30 days., Proportion of patients converted to guideline-based therapy according to algorithm as described in the section titled “Procedures, patient monitoring and data collection”., Proportion of patients readmitted, admitted to ICU or dead at 30 days., CRP on day 5, continuous and binary (higher than on any day from 1 to 4 including baseline)., MAP ≤ 65 OR respiratory frequency > 25 OR pulse > 100 OR needing supplemental oxygen (1-4 of these fulfilled) on day 5., PCT on day 5, continuous and binary (higher than on any day from 1 to 4 including baseline), Temperature ≥ 38.0 on day 5., Patient reported outcome measurements: Changes in Visual Analogue Scales for dyspnoea, cough, and fatigue

—

Countries

Denmark

Outcome results

None listed